

SIRT6 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP14024b**Specification****SIRT6 Antibody (C-term) Blocking peptide -
Product Information**Primary Accession [Q8N6T7](#)**SIRT6 Antibody (C-term) Blocking peptide -
Additional Information****Gene ID** 51548**Other Names**NAD-dependent protein deacetylase
sirtuin-6, 351-, Regulatory protein SIR2
homolog 6, SIR2-like protein 6, SIRT6,
SIR2L6**Target/Specificity**The synthetic peptide sequence used to
generate the antibody AP14024b was
selected from the C-term region of SIRT6. A
10 to 100 fold molar excess to antibody is
recommended. Precise conditions should be
optimized for a particular assay.**Format**Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.**Storage**Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.**Precautions**This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.**SIRT6 Antibody (C-term) Blocking peptide -
Protein Information****Name** SIRT6**Synonyms** SIR2L6**SIRT6 Antibody (C-term) Blocking peptide
- Background**

NAD-dependent protein deacetylase. Has
deacetylase activity towards 'Lys-9' and
'Lys-56' of histone H3. Modulates acetylation of
histone H3 in telomeric chromatin during the
S-phase of the cell cycle. Deacetylates 'Lys-9'
of histone H3 at NF-kappa-B target promoters
and may down-regulate the expression of a
subset of NF-kappa-B target genes.
Deacetylation of nucleosomes interferes with
RELA binding to target DNA. May be required
for the association of WRN with telomeres
during S-phase and for normal telomere
maintenance. Required for genomic stability.
Required for normal IGF1 serum levels and
normal glucose homeostasis. Modulates
cellular senescence and apoptosis. Regulates
the production of TNF protein (By similarity).

Function

NAD-dependent protein deacetylase involved in various processes including telomere maintenance and gene expression, and consequently has roles in genomic stability, cell senescence and apoptosis (PubMed:18337721, PubMed:19135889, PubMed:19625767, PubMed:21362626). Has very weak deacetylase activity and can bind NAD(+) in the absence of acetylated substrate (PubMed:21362626). Has deacetylase activity towards histone H3K9Ac and H3K56Ac (PubMed:19625767, PubMed:21362626). Modulates acetylation of histone H3 in telomeric chromatin during the S-phase of the cell cycle (PubMed:19625767). May also be required for the association of WRN with telomeres during S-phase and for normal telomere maintenance (PubMed:18337721). Deacetylates histone H3K9Ac at NF-kappa-B target promoters and may down-regulate the expression of a subset of NF-kappa-B target genes (PubMed:21362626). Deacetylation of nucleosomes interferes with RELA binding to target DNA (PubMed:19135889). Acts as a corepressor of the transcription factor Hif1a to control the expression of multiple glycolytic genes to regulate glucose homeostasis (By similarity). Required for normal IGF1 serum levels and normal glucose homeostasis (By similarity).

Regulates the production of TNF protein (By similarity). Has a role in the regulation of life span (By similarity).

Cellular Location

Nucleus, nucleoplasm. Note=Predominantly nuclear. Associated with telomeric heterochromatin regions

**SIRT6 Antibody (C-term) Blocking peptide
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)